# Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

> **NCT04936230** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Urothelial Carcinoma
- Platinum-Resistant Urothelial Carcinoma
- Stage IV Bladder Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT04936230
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-22
- **Primary completion:** 2024-08-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04936230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04936230, "Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT04936230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*